BUSINESS
Nichi-Iko Aims at Overseas Sales of 60 Billion Yen in FY2021; Infliximab Biosimilar in the US to Play Key Role
Nichi-Iko Pharmaceutical intends to increase its overseas sales to 60 billion yen in the year ending March 2022, primarily by launching a biosimilar version of Remicade (infliximab) in the US market, President Yuichi Tamura said on May 14. For the…
To read the full story
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





